Search

Your search keyword '"Zuleger, Cindy L"' showing total 10 results
Start Over Author "Zuleger, Cindy L" Search Limiters Available in Library Collection
10 results on '"Zuleger, Cindy L"'

2. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma

Author

Albertini, Mark R., Yang, Richard K., Ranheim, Erik A., Hank, Jacquelyn A., Zuleger, Cindy L., Weber, Sharon, Neuman, Heather, Hartig, Greg, Weigel, Tracey, Mahvi, David, Henry, Mary Beth, Quale, Renae, McFarland, Thomas, Gan, Jacek, Carmichael, Lakeesha, Kim, KyungMann, Loibner, Hans, Gillies, Stephen D., and Sondel, Paul M.

Published
2018
Full Text
View/download PDF

4. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting

Author

Magee, Kara, primary, Marsh, Ian R., additional, Turek, Michelle M., additional, Grudzinski, Joseph, additional, Aluicio-Sarduy, Eduardo, additional, Engle, Jonathan W., additional, Kurzman, Ilene D., additional, Zuleger, Cindy L., additional, Oseid, Elizabeth A., additional, Jaskowiak, Christine, additional, Albertini, Mark R., additional, Esbona, Karla, additional, Bednarz, Bryan, additional, Sondel, Paul M., additional, Weichert, Jamey P., additional, Morris, Zachary S., additional, Hernandez, Reinier, additional, and Vail, David M., additional

Published
2021
Full Text
View/download PDF

7. Abstract 2538: Immune responses to common melanoma-associated antigens following intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma

Author

Zuleger, Cindy L., primary, Sondel, Paul M., additional, Hank, Jacquelyn A., additional, Ranheim, Erik A., additional, McFarland, Thomas A., additional, Collins, Jennifer, additional, Clements, Erin, additional, Whalen, Giles, additional, Galili, Uri, additional, and Albertini, Mark R., additional

Published
2014
Full Text
View/download PDF

8. Clonal Expansions of 6-Thioguanine Resistant T Lymphocytes in the Blood and Tumor of Melanoma Patients1

Author

Albertini, Mark R., Macklin, Michael D., Zuleger, Cindy L., Newton, Michael A., Judice, Stephen A., and Albertini, Richard J.

Subjects
Hypoxanthine Phosphoribosyltransferase, T-Lymphocytes, Drug Resistance, Receptors, Antigen, T-Cell, Lymphocyte Activation, Article, Clone Cells, Lymphocytes, Tumor-Infiltrating, Neoplasms, Mutation, Humans, Thioguanine, Melanoma, Cell Proliferation
Abstract

The identification of specific lymphocyte populations that mediate tumor immune responses is required for elucidating the mechanisms underlying these responses and facilitating therapeutic interventions in humans with cancer. To this end, mutant hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficient (HPRT-) T-cells were used as probes to detect T-cell clonal amplifications and trafficking in vivo in patients with advanced melanoma. Mutant T-cells from peripheral blood were obtained as clonal isolates or in mass cultures in the presence of 6-thioguanine (TG) selection and from tumor-bearing lymph nodes (LNs) or metastatic melanoma tissues by TG-selected mass cultures. Nonmutant (wild-type) cells were obtained from all sites by analogous means, but without TG selection. cDNA sequences of the T-cell receptor (TCR) beta chains (TCR-beta), determined directly (clonal isolates) or following insertion into plasmids (mass cultures), were used as unambiguous biomarkers of in vivo clonality of mature T-cell clones. Clonal amplifications, identified as repetitive TCR-beta V-region, complementarity determining region 3 (CDR3), and J-region gene sequences, were demonstrated at all sites studied, that is, peripheral blood, LNs, and metastatic tumors. Amplifications were significantly enriched among the mutant compared with the wild-type T-cell fractions. Importantly, T-cell trafficking was manifested by identical TCR-beta cDNA sequences, including the hypervariable CDR3 motifs, being found in both blood and tissues in individual patients. The findings described herein indicate that the mutant T-cell fractions from melanoma patients are enriched for proliferating T-cells that infiltrate the tumor, making them candidates for investigations of potentially protective immunological responses.

Published
2008

9. MAGE-C2 Promotes Growth and Tumorigenicity of Melanoma Cells, Phosphorylation of KAP1, and DNA Damage Repair

Author

Bhatia, Neehar, primary, Xiao, Tony Z., additional, Rosenthal, Kimberly A., additional, Siddiqui, Imtiaz A., additional, Thiyagarajan, Saravanan, additional, Smart, Brendan, additional, Meng, Qiao, additional, Zuleger, Cindy L., additional, Mukhtar, Hasan, additional, Kenney, Shannon C., additional, Albertini, Mark R., additional, and Jack Longley, B., additional

Published
2013
Full Text
View/download PDF

10. A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients

Author

Cassaday, Ryan D., primary, Sondel, Paul M., additional, King, David M., additional, Macklin, Michael D., additional, Gan, Jacek, additional, Warner, Tom F., additional, Zuleger, Cindy L., additional, Bridges, Alan J., additional, Schalch, Heidi G., additional, Kim, Kyung Mann, additional, Hank, Jacquelyn A., additional, Mahvi, David M., additional, and Albertini, Mark R., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results